fbpx Skip to main content

Member's Profile

Aerie Pharmaceuticals

2030 Main St Ste 1400
Irvine,   California
United States
Membership Info
Membership Type: Industry
Membership Since: 2013
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About Aerie Pharmaceuticals
Biotech Company
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye. In the United States, Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and the fixed-dose combination Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Aerie has operations in Europe and Japan, and is building its ophthalmology pipeline, including clinical stage candidates in dry eye and retina and discovery programs based on its proprietary library of small-molecule multi-kinase inhibitors.
Related News
No related news posted by this Member